ENXTPA:NANOBiotechs
Do Early NBTXR3 Data Reveal a Shift in Nanobiotix’s (ENXTPA:NANO) Competitive Positioning?
Nanobiotix recently announced updated results from phase 1 trials of its radiotherapy-activated candidate NBTXR3 in esophageal adenocarcinoma and recurrent or metastatic head and neck squamous cell carcinoma, presented at the 2025 ASTRO Annual Meeting by clinical investigators from MD Anderson Cancer Center and University of North Carolina.
These early-stage clinical findings suggest potential for NBTXR3 across multiple solid tumor types, bolstered by continued regulatory Fast Track...